TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01006317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical skills training
Description: In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education
Description: In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: financial
Description: In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
Study: NCT00770432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, maltodextrin 500 powder for solution
Description: Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
Study: NCT04093921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET-based therapy
Description: see previous

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: To include all recommended outpatient treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: To include all recommended outpatient treatments
Study: NCT03361826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro MST with Cool TwinCoil
Description: MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DBT
Description: Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
Study: NCT02875301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 150 Minutes Week
Description: This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 225 Minutes Week
Description: This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretch and Tone
Description: The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
Study: NCT04154215

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT FDG brain scan
Description: Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated.
Study: NCT01767935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Undergo cryosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02999425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational intervention
Study: NCT02861144

Intervention type: OTHER
Group type: OTHER
Intervention: Ma ka hana ka ̒ike
Description: Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Hanapū Provider Toolbox
Description: Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
Study: NCT01338012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study: NCT00439829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal F
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal F
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide
Description: * 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: - 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: - 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter
Study: NCT02091739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (100 Units)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (75 Units)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT01705808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Protein C concentrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protein C concentrate
Study: NCT01250964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens insertion during cataract surgery
Description: After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens insertion during cataract surgery
Description: After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
Study: NCT00405353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel 10 grams of gel containing 100 mg of testosterone
Description: testosterone gel
Study: NCT00823004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: letrozole 5mg/day from day 3 to day 7 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive (Marvelone)
Description: oral contraceptive, first 21 days
Study: NCT02228239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Mirtazapine)
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
Study: NCT01760486

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island
Study: NCT00823004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive (Marvelone)
Description: oral contraceptive, first 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist (buserelin)
Description: 50 µg SC twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH or hMG
Description: recombinant FSH or hMG 300-450 IU/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH or hMG
Description: recombinant FSH or hMG 300-450 IU/day
Study: NCT01760486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape Up Rhode Island + Professional Coach + Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape Up Rhode Island + Peer Coach + Incentives
Study: NCT03229447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLearning Modules
Description: All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eLearning Modules
Description: All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change Team Intervention
Description: Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
Study: NCT01075230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
Study: NCT01760967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intervention to administer dexmedetomidine or not

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intervention to administer dexmedetomidine or not
Study: NCT00823004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganirelix acetate
Description: GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
Study: NCT00211978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium acetate
Description: 667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
Study: NCT01903928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: injection
Study: NCT01189617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PD-F-7619
Description: Off-White to Beige Lotion
Study: NCT03380221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon
Description: Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat cookies
Description: Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
Study: NCT00545246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (AVE0005)
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: intravenous infusion
Study: NCT01729338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \[10,12,14, etc.\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide (odd cycles \[9,11,13, etc.\]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately.
Study: NCT00395941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Acitretin
Study: NCT02205008

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: Total or subtotal gastrectomy with D2

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgery
Description: Total or subtotal gastrectomy with D2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant systemic chemotherapy
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: adjuvant systemic chemotherapy
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early postoperative intraperitoneal chemothgerapy
Description: operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
Study: NCT04014166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
Study: NCT05028127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be receiving bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be receiving bimekizumab at pre-specified time-points.
Study: NCT02716831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling & Acceptance-based Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Eating Disorders
Study: NCT00532194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cediranib
Description: Once-daily oral tablet starting dose 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cediranib
Description: Once-daily oral tablet starting dose 20mg